Company release, Inside information
30 August 2023 at 6:35 p.m. (EEST)
Nightingale Health Plc (“Nightingale Health”), a pioneer in health risk detection and preventative health, and Finland's largest health service company Suomen Terveystalo Oy ("Terveystalo"), have signed an agreement that expands the partnership between the two companies to cover Terveystalo's occupational health services. Nightingale Health announced a letter of intent to expand the partnership on 30 June 2023, and the now signed agreement incorporates Nightingale Health's blood analysis technology to regular health checks performed as part of Terveystalo's occupational health services.
Terveystalo will use Nightingale Health’s risk prediction models and blood values in regular health checks and integrate them into the daily work of Terveystalo’s occupational health doctors, nurses, and laboratories. The agreement is a significant achievement for Nightingale Health, as it is the first agreement where the company’s blood analysis technology will be part of an occupational health system on a national scale.
Terveystalo is Finland's largest occupational health service provider, and it offers occupational health services to more than 27,000 companies and other organizations. Its occupational health services cover approximately 700,000 individuals, a significant proportion of Finland’s total workforce. Using Nightingale Health's risk prediction models in regular health checks makes it achievable to prevent diseases on a population-level.
Nightingale Health's blood biomarker-based risk prediction models can detect disease risks for several common chronic diseases from a single blood sample with a single test. A group of Terveystalo’s medical professionals have selected the risk prediction to cover eight critical chronic diseases:
- myocardial infarction;
- cardiovascular disease;
- type 2 diabetes;
- liver fibrosis and cirrhosis;
- chronic kidney disease;
- lung cancer; and
- alcoholic liver disease.
The ability to identify the risks for several common diseases from a single sample in one test is a significant improvement compared to current risk assessments, which are conducted based on individual blood values, clinical examination, and patient interviews. By including Nightingale Health's risk prediction models in regular health checks, health risks are identified well in advance and actions can be started to prevent diseases.
Terveystalo will also use Nightingale Health’s blood analysis technology to conduct follow-up examinations, which quantify the impact of the actions prescribed by healthcare professionals based on existing guidelines. Since Terveystalo's occupational health services serve a significant part of Finland's working-age population, reducing the risk of illness positively affects the whole population's health.
Marja-Leena Tuomola, Chief Commercial Officer, Terveystalo:
"Many common chronic diseases (e.g., diabetes and cardiovascular diseases) directly affect working ability and performance and require continuous monitoring, which causes a strain on the healthcare system. However, a significant proportion of chronic diseases in the working-age population can be prevented. We need innovative solutions for impactful preventative care, which Terveystalo and Nightingale Health's close cooperation offers. When we can prevent chronic diseases, we can reduce the negative impacts the diseases cause on society and the national economy while promoting the health and well-being of individuals."
Teemu Suna, CEO and Founder, Nightingale Health:
"We are honored to be working towards building a healthier future for Finns together with Terveystalo. Nightingale Health's comprehensive health risk assessments will significantly increase the efficacy and impact of regular health checks. Our technology detects the risks of the most common chronic diseases more extensively, with less work and without compromising detection accuracy compared to existing risk assessments. This equips healthcare professionals with advanced and user-friendly clinical tools. When the tools of healthcare professionals improve, diseases can be better prevented, and the entire healthcare system is reformed to work in a more preventative and efficient way."
Nightingale Health's blood analysis technology can be integrated to Terveystalo’s existing operating procedures in a straightforward way since the risk predictions are provided from one standard blood sample. The results are delivered to healthcare professionals in an easy-to-understand format and can be acted upon based on existing clinical guidelines. In addition to the risk predictions, occupational health doctors and nurses will receive individual blood values used for diagnostics.
Jukka Pitkänen, Chief Medical Officer, Occupational Health, Terveystalo:
"Nightingale Health’s blood analysis technology brings more clarity to the work of healthcare professionals and a better opportunity to focus on the customer. These advancements are enabled by the professional always having personalized metabolic biomarker-based risk predictions of each customer which can be used to support clinical work."
The implementation of Nightingale Health's blood analysis in Terveystalo's regular health checks is expected to start in January 2024.
For further information, please contact:
Teemu Suna, CEO
Oaklins Merasco Ltd, tel. +358 9 6129 670
About Nightingale Health
Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.
Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 25 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 450 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com
Terveystalo in brief
Terveystalo is the largest private healthcare service provider in Finland in terms of revenue and network. Terveystalo is also a leading occupational health provider in the Nordic region. We offer a wide variety of primary health care, specialized care, and well-being services for corporate and private customers and the public sector. Terveystalo’s s digital services are available 24/7, regardless of time and place. Health and well-being services are also provided by over 370 clinics across Finland. In Sweden, we offer occupational health services at 155 clinics. Terveystalo is listed on the Helsinki Stock Exchange.
In 2022, Terveystalo had approximately 1.3 million individual customers in Finland and the number of customer appointments was approximately 8.5 million, with more than a quarter of these being conducted via remote channels. Terveystalo employs over 16,800 healthcare and well-being professionals. www.terveystalo.com